Division of Gastroenterology, Department of Medicine Hospital of the University of Pennsylvania, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.
Am J Gastroenterol. 2019 Jan;114(1):64-70. doi: 10.1038/s41395-018-0374-3.
Barrett's esophagus and esophageal adenocarcinoma continue to present considerable management challenges in the Western world. Despite our best efforts to date, the prognosis of advanced esophageal adenocarcinoma remains poor and far too many individuals with esophageal adenocarcinoma have not had a prior endoscopy to detect Barrett's esophagus. As such, current strategies of screening for Barrett's esophagus and subsequent surveillance need to be further optimized. Screening today is limited to high definition white light endoscopy in high-risk patient populations and as such has multiple limitations. However, a variety of exciting new techniques including risk prediction tools, tethered capsule endomicroscopy, a cytology sponge, breath testing for exhaled volatile organic compounds, and assessment of the oral microbiome are now under study in an effort to develop less expensive population-based screening methods. Similarly, endoscopic surveillance, as currently practiced has a variety of limitations. Inexpensive readily available adjuncts are already available to optimize surveillance including increased inspection time in an effort to detect mucosal or vascular abnormalities, special attention to the right hemisphere of the esophagus, and utilization of narrow band imaging or other electronic chromoendoscopy techniques. To improve endoscopic surveillance, a variety of new paradigms are under study including wide area trans-epithelial sampling, advanced endoscopic imaging, molecular imaging, clinical risk stratification and utilization of biomarkers of increased risk. However, progress will be challenging due to the complexity of esophageal cancer biology and the rarity of progression to cancer among patients with nondysplastic Barrett's epithelium.
巴雷特食管和食管腺癌在西方世界仍然存在相当大的管理挑战。尽管我们迄今为止已经尽了最大努力,但晚期食管腺癌的预后仍然很差,而且太多患有食管腺癌的人没有进行过内窥镜检查来发现巴雷特食管。因此,目前筛查巴雷特食管和随后进行监测的策略需要进一步优化。目前的筛查仅限于高危人群的高清白光内窥镜检查,因此存在多种局限性。然而,包括风险预测工具、系绳胶囊内镜、细胞学海绵、呼气挥发性有机化合物检测和口腔微生物组评估在内的各种令人兴奋的新技术目前正在研究中,以开发更经济实惠的基于人群的筛查方法。同样,目前的内镜监测也存在多种局限性。一些廉价且易于获得的辅助手段已经可以用于优化监测,包括增加检查时间以检测黏膜或血管异常、特别注意食管的右半球,以及利用窄带成像或其他电子染色内镜技术。为了改进内镜监测,目前正在研究各种新的方法,包括大面积跨上皮采样、先进的内镜成像、分子成像、临床风险分层和利用高风险生物标志物。然而,由于食管癌生物学的复杂性和非异型性巴雷特食管患者进展为癌症的罕见性,进展将具有挑战性。
Gastrointest Endosc Clin N Am. 2021-1
Curr Opin Gastroenterol. 2009-7
Curr Opin Gastroenterol. 2012-7
Dig Dis Sci. 2009-8-11
Gastroenterology. 2023-4
Curr Gastroenterol Rep. 2019-7-25
Gastrointest Endosc Clin N Am. 2021-1